Impact News +++ AKTIE IM FOKUS: Secunet auf Einjahrestief - Zahlen keine Erleichterung (DPA-AFX) +++ SECUNET Aktie -3,71%

REGENXBIO Aktie

>REGENXBIO Aktienkurs

6.9 EUR +3.0% (TradegateBSX)

Ask: 6.95 EUR / 438 Stück

Bid: 6.8 EUR / 451 Stück

Tagesumsatz: 789 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENXBIO Aktie über LYNX handeln

Intraday

1 Jahr

>REGENXBIO Performance

1 Woche: -1,4%

1 Monat: -8,0%

3 Monate: -45,2%

6 Monate: -15,3%

1 Jahr: -4,8%

laufendes Jahr: -43,4%

>REGENXBIO Aktie

Name:

REGENXBIO INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US75901B1070 / A140E0

Symbol/ Ticker:

RB0 (Frankfurt) / RGNX (NASDAQ)

Kürzel:

FRA:RB0, ETR:RB0, RB0:GR, NASDAQ:RGNX

Index:

Webseite:

https://www.regenxbio.com..

Profil:

Regenxbio Inc. is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies to treat genetic disorders through its proprietary NAV Technology Platform. This platform utilizes recombinant adeno-associated ..
>Volltext..

Marktkapitalisierung:

348.05 Mio. EUR

Unternehmenswert:

374.02 Mio. EUR

Umsatz:

148.11 Mio. EUR

EBITDA:

-126.51 Mio. EUR

Nettogewinn:

-168.48 Mio. EUR

Gewinn je Aktie:

-3.26 EUR

Schulden:

226.39 Mio. EUR

Liquide Mittel:

29.95 Mio. EUR

Operativer Cashflow:

-107.72 Mio. EUR

Bargeldquote:

1.95

Umsatzwachstum:

80.28%

Gewinnwachstum:

24.75%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 53.033 USD.

Suchwörter:

REGENXBIO

Letzte Datenerhebung:

30.03.26

>REGENXBIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 51.61 Mio. St.

Frei handelbar: 89.02%

Leerverk. Aktien: 12.53%

Rückkaufquote: -0.25%

Mitarbeiter: 371

Umsatz/Mitarb.: 0.4 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 273.02%

Bewertung:

KGV: -

KGV lG: -

KUV: 2.5

KBV: 3.93

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 78.93%

Gewinnmarge: -113.75%

Operative Marge: -94.58%

Managementeffizenz:

Gesamtkaprendite: -42.19%

Eigenkaprendite: -107%

>REGENXBIO Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>REGENXBIO Chart & Kurs - NASDAQ

>REGENXBIO News

30.03.26 - 10:21	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

30.03.26 - 10:09	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
	LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder......

30.03.26 - 10:03	RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange......

29.03.26 - 14:09	RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like......

26.03.26 - 14:02	SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD (PR Newswire)
	Notice to Pension Funds, Asset Managers, and Fiduciaries NEW YORK, March 26, 2026 /PRNewswire/ -- Institutional investors holding positions in REGENXBIO, Inc. (NASDAQ: RGNX) during the period between February 9, 2022 and January 27, 2026 may wish to evaluate lead plaintiff opportunities......

24.03.26 - 23:39	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

22.03.26 - 14:30	RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like......

20.03.26 - 01:12	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

18.03.26 - 14:57	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
	Executive Accountability: Stephen Pakola, M.D. Named in REGENXBIO Securities Action NEW YORK, March 18, 2026 /PRNewswire/ -- Stephen Pakola, M.D., REGENXBIO's Executive Vice President and Chief Medical Officer, is named as an individual defendant in a securities class action alleging that......

17.03.26 - 19:54	RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like......

13.03.26 - 22:57	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 13, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

13.03.26 - 03:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Regenxbio im Wert von 53033 USD (Insiderkauf)
	Pakola, Steve - Vorstand - Tag der Transaktion: 2026-03-10...

12.03.26 - 15:03	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX (PR Newswire)
	NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......

11.03.26 - 16:48	REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 (PR Newswire)
	Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional measures at 1 year, including participants aged 8+ Cardiac MRI data for pivotal dose patients......

11.03.26 - 14:39	RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like......

09.03.26 - 16:30	Regenxbio präsentiert strategische Fortschritte und Ausblick für wichtige Medikamenten-Pipeline (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

08.03.26 - 21:45	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

06.03.26 - 19:18	The Analyst Verdict: Regenxbio In The Eyes Of 8 Experts (Benzinga)
	Latest Ratings for RGNX DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsMarket Perform Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for RGNX View the Latest Analyst Ratings Importance Rank: 1 read more...

06.03.26 - 14:51	RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like......

05.03.26 - 23:48	Regenxbio outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Tiefe des menschlichen Herzens läßt sich nicht ausloten. - Sprichwort China

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram